Alignment Ventures

About The Fund

Alignment Ventures is a venture capital firm specializing in early-stage investments, specifically providing seed-stage venture capital for life science startups. They focus on strategic sectors including biotech, medical device, health care IT, and life sciences. With an investment approach rooted in close collaboration with university technology and taking on interim executive roles within their companies, they aim to prepare startups for subsequent investment rounds. They invest up to $416,000,000, both their own capital and raised non-dilutive funds, engaging hands-on in technology licensing, IP strategy, market research, and the recruitment of expert management teams. Alignment Ventures' team, boasting over a century of combined experience, comprises seasoned professionals who have played pivotal roles in starting, building, financing, and exiting life science enterprises. These partners offer their vast expertise to startups, nurturing them through to Series A financing and beyond. Their work involves intricate tasks such as designing and executing risk-reducing experiments that establish commercial proof of concept, crafting business strategies, writing business plans and financial models, analyzing markets and competitors, and outlining a comprehensive financing strategy. Notably, they don't stop at investing but also aid in appointing the right long-term CEO with an appropriate operational background, after which they raise the next financing round. Alignment Ventures has extensive experience with multiple successful collaborations and investments, having previously run or co-invested with prominent firms such as Avalon, Kleiner, ARCH, and more. The team, led by Michael Tippie and Scurry Johnson, includes individuals like Gerardo Noriega and Dr. George Christ who bring niche expertise and innovation to the fund. Portfolio companies like TomegaVax, NeuraMedica, and PercAssist highlight their successful approach, demonstrating products and services that save lives or reduce morbidity significantly.